20th Oct 2014 07:00
20 October 2014
Biofrontera AG
("Biofrontera" or the "Company")
Appointment of Shore Capital as Nominated Adviser & Broker
Biofrontera AG (AIM/FSE: B8F), the biopharmaceutical company focusing on skin cancer, is pleased to announce the appointment of Shore Capital and Corporate Limited as Nominated Adviser and Shore Capital Stockbrokers Limited as sole broker, (together "Shore Capital"), with immediate effect.
Ends.
For enquiries, please contact:
Biofrontera AG |
|
Prof. Hermann Lübbert, Chief Executive Officer Thomas Schaffer , Chief Financial Officer | Tel: + 49 (0) 214 87632 22 |
|
|
Nomad and Broker: Shore Capital | Tel: +44(0) 20 7220 0500 |
Bidhi Bhoma / Toby Gibbs |
|
|
|
Investor Relations: Seton Services | Tel: +44(0) 20 7603 6797 |
Toni Vallen |
|
|
|
Financial PR: Gable Communications John Bick | Tel: +44(0) 20 7193 7463 Tel: +44 (0)7872 061007 |
Notes to Editors:
Biofrontera AG(AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs and medical cosmetics for the treatment and care of skin diseases. Biofrontera's main product is Ameluz(R) , a prescription drug approved for use in Europe for the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by photodynamic therapy (light therapy). Biofrontera is the first small German pharmaceutical company to receive a centralized approval for a drug developed in-house. The Company is looking to further develop Ameluz(R) for use in Basal Cell Carcinoma and is currently progressing through regulatory approvals to sell the product in other territories, in particular the largest pharmaceutical market, the USA.
In addition, the Company markets the Belixos(R) cosmetic series with plant extracts, currently available in cream and liquid formulations which offer nurturing and regenerating effects for people suffering from pruritus, dry skin or chronic ailments such as eczema or psoriasis.
Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the CEO, and is headquartered in Leverkusen, Germany.
www.biofrontera.com
Related Shares:
B8F.L